Skip to content
Menu

Alnylam Pharmaceuticals, Inc. ALNY

Full chart Compare
Set alert

Price alert · ALNY

All alert types
158.69 USD -1.04 (-0.65%)

As ofNov 17, 2026, 9:43 AM EST

158.67 Day range 160.64
149.18 52-week range 479.79
YTD
-60.09%
1 year
-65.54%
Market cap
21.25B
Revenue (ttm)
5.01B
Profit margin
52.85%
EPS (ttm)
19.80
Shares out
133.94M
P/E ratio
8.01
Forward P/E
14.72
YTD return
-60.09%
1-year return
-65.54%
50-day average
219.25
Volume
47.75K
Avg volume
2.06M
Open
159.02
Previous close
159.73
Day's range
158.67 – 160.64
52-week range
149.18 – 479.79
Beta
0.44
Analysts
Buy
Price target
299.96 (+89.0%)
Earnings date
Feb 11, 2027

5D +4.05 (+2.60%)

150160TueWedThuFriMon159.73

Key statistics

200-day average
275.49
Enterprise value
21.51B
PEG ratio
0.22
Price / sales
4.27
Price / book
5.93
Revenue growth
16.70%
Free cash flow
327.23M
Total cash
3.59B
Total debt
3.00B
Return on equity
138.07%
Short % of float
5.44%

Fundamental scorecard

15 of 25 checks passed on ALNY’s reported financials

ValueGrowthProfitabilityHealthDividend

15of 25 checks passed

  • Value 3 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ALNY Revenue — quarterly 1.46B
ALNY Net income — quarterly 2.17B
ALNY EPS — quarterly 16.19

Earnings

ALNY recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 20261.72———
Oct 29, 2026Sep 30, 20261.6616.26+14.60+879.52%
Jul 30, 2026Jun 30, 20261.631.21-0.42-25.77%
Apr 30, 2026Mar 31, 20260.8721.51+0.64+73.17%
Feb 12, 2026Dec 31, 20251.160.82-0.34-29.31%
Oct 30, 2025Sep 30, 20250.5611.84+1.28+227.99%

Upgrades / downgrades

ALNY analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026BarclaysmainOverweightOverweight
Nov 2, 2026Truist SecuritiesdownBuyHold
Nov 2, 2026Canaccord GenuitymainBuyBuy
Oct 30, 2026UBSmainBuyBuy
Oct 30, 2026TD CowenmainBuyBuy
Oct 30, 2026BernsteindownOutperformMarket Perform

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
alnylam.com

News

Your note

Sign in to keep a note on ALNY — it syncs with the Stock Master app.

Insider holders

ALNY insider holders
InsiderRelationLatest transactionDateShares held
BONNEY MICHAEL WDirectorSaleAug 17, 202520,804
FITZGERALD KEVIN JOSEPHOfficerSaleMar 4, 202621,106
GARG PUSHKALOfficerSaleMar 4, 202619,374
GREENSTREET YVONNE LChief Executive OfficerStock Award(Grant)Sep 17, 202696,209
POULTON JEFFREY VChief Financial OfficerSaleMar 3, 202661,862
PYOTT DAVID E IDirectorSaleMay 31, 202629,482

Institution ownership

ALNY institution ownership
Holder% heldSharesValueReported
Capital World Investors10.32%13,819,8442.21BSep 29, 2026
FMR, LLC9.42%12,622,4982.02BSep 29, 2026
Blackrock Inc.8.23%11,020,0451.76BSep 29, 2026
Capital Research Global Investors8.17%10,940,9051.75BSep 29, 2026
Vanguard Portfolio Management LLC5.00%6,697,9201.07BSep 29, 2026
Vanguard Capital Management LLC4.49%6,018,111961.27MSep 29, 2026

Fund ownership

ALNY fund ownership
Holder% heldSharesValueReported
Growth Fund of America6.69%8,960,4871.43BSep 29, 2026
Amcap Fund3.38%4,526,680723.05MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.16%4,239,087677.11MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.16%2,893,030462.10MJun 29, 2026
Invesco QQQ Trust, Series 12.09%2,794,074446.30MSep 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund1.60%2,136,580341.28MJul 30, 2026